Results 141 to 150 of about 165,062 (263)
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart +14 more
wiley +1 more source
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan +7 more
wiley +1 more source
Selskyy P. R., Furdela M. Ya., Selskyy B. P. Нарушение клеточного звена общего иммунитета у больных с различными видами эндоцервикоза = Violation of the total cellular immunity in patients with different types of endocervicosis.
P. R. Selskyy +2 more
doaj
Electrical and mechanical activity of the cervix in the ewe during pregnancy and parturition [PDF]
Pierre‐Louis Toutain +3 more
openalex +1 more source
Objective Foot orthoses are thought to improve pain by potentially modifying internal mechanical forces. To test this, we explored whether foot orthoses can modify patterns of bone marrow lesions (BMLs) in people with midfoot pain. Methods Forty‐two people were recruited with midfoot pain, and magnetic resonance imaging–confirmed midfoot BMLs ...
Jill Halstead +4 more
wiley +1 more source
Cesarean in the second stage: a possible risk factor for subsequent spontaneous preterm birth. [PDF]
Berghella, Vincenzo +3 more
core +2 more sources
Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava +48 more
wiley +1 more source
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti +19 more
wiley +1 more source

